← All Checkpoint Therapeutics, INC filings

Checkpoint Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

CKPT
Checkpoint Therapeutics, INC
10-K: Checkpoint Therapeutics Reports 2024 Results, Highlights UNLOXCYT Approval and Merger Agreement with Sun Pharma
Checkpoint Therapeutics' 2024 10-K filing highlights the FDA approval of UNLOXCYT and a pending merger with Sun Pharmaceutical Industries, while also detailing the company's financial losses and future strategies.
CKPT
Checkpoint Therapeutics, INC
10-K: Checkpoint Therapeutics Outlines Capital Structure and Development Pipeline in 10-K Filing
Checkpoint Therapeutics' 10-K filing details its capital structure, ongoing clinical programs, and financial position, highlighting both opportunities and challenges.